AURIGEN MEDICAL LIMITED

Their core work

AuriGen Medical is an Irish medical device SME developing implantable and catheter-based technologies to treat persistent atrial fibrillation — the most common sustained cardiac arrhythmia and a leading cause of stroke and heart failure. Their core work targets the left atrial appendage (LAA), a small pouch in the heart where blood clots form and where rogue electrical signals drive persistent AF. They combine mechanical implant design with electrical isolation and bio-photonic optical confirmation to treat both the clot risk and the arrhythmia itself in a single procedure. Both of their H2020 projects coordinate clinical-stage development of this device platform.

What they specialise in

How they've shifted over time

Their first H2020 grant (AuriGen, 2018) scoped a broad LAA implant addressing arrhythmia, stroke, and heart failure through occlusion plus electrotherapy. By LAA-START in 2019, the focus tightened to electrical isolation of the LAA with bio-photonic optical confirmation for intraoperative verification. The direction is away from a multi-indication implant and toward a more targeted electrophysiology tool with real-time procedural feedback.

They are moving from mechanical occlusion toward electrophysiology-led procedures with intraoperative imaging feedback, which makes them relevant partners for cardiac mapping, optical sensing, and minimally invasive catheter technology collaborators.

How they like to work

AuriGen leads its own work — both H2020 grants are SME-instrument awards where they are the coordinator, with only four unique partners across three countries. This is a tightly focused, founder-led clinical SME rather than a consortium-builder. Partnering with them means engaging a single-product company that owns its IP and drives its own clinical roadmap.

Small, purposeful network: 4 partners across 3 countries, consistent with an SME-instrument funding pattern rather than a broad research consortium. Geographic footprint is European and focused.

What sets them apart

Very few European SMEs combine LAA mechanical occlusion, electrical isolation, and intraoperative optical confirmation in a single device pipeline — AuriGen does. They sit at the intersection of structural heart intervention and electrophysiology, two traditionally separate cardiology specialties. For partners in cardiac imaging, ablation catheters, or AF clinical trials, they offer a focused clinical-stage platform rather than a broad R&D portfolio.

Highlights from their portfolio

• AuriGen
  Their largest H2020 grant at EUR 2.45M under the SME-2 scheme, funding the next-generation LAA implant that defines the company.
• LAA-START
  Innovation Action introducing bio-photonic optical confirmation to LAA electrical isolation — an unusual crossover between photonics and electrophysiology.